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Abstract
The term leishmaniasis encompasses a spectrum of vector-borne protozoan parasitic
diseases ranging from self-healing cutaneous to fatal visceral leishmaniasis. The disease
affects 12 million people worldwide with 0.5 million new cases per annum. Present
antileishmanial chemotherapeutic drugs project limitations because of severe toxicity,
lengthy regime and occurrence of resistance, thereby making development of newer,
gentler and efficacious therapeutics an urgent need for treatment of leishmaniasis.
Application of medicinal plants in treatment of refractory diseases is valued for its clinical
efficacy and nontoxicity. The biologically active components derived from them continue
to play important roles as chemopreventive agents. Licorice has been known for its
medicinal property from ancient times for treatment of various ailments. 18β-Glycyrrhe-
tinic  acid,  glycyrrhizic  acid  and  licochalcone  A  are  the  most  extensively  studied
constituents of licorice in terms of antileishmanial agent. Overall, this chapter is dedicated
to highlight the current understanding of the mechanism of these bioactive constituents
of licorice, which potentiates them as antileishmanial agents. Furthermore, it also brings
to light the importance of folk medicine in curing diseases and thereby gives impetus to
explore ancient medicines and thier mode of actions to use them progressively to cure
diseases.
Keywords: 18β-glycyrrhetinic acid, glycyrrhizic acid, licochalcone A, antileishmanial,
cytokines
1. Introduction
This chapter is dedicated to understand the mode of action of specific constituents of licorice,
which have been isolated and characterized as antileishmanial agents. Among over 20 triterpi-
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noids and 300 flavanoids present and characterized in licorice, only three, namely 18β-glycyr-
rhetinic  acid,  glycyrrhizin  and  licochalcone  A,  have  been  extensively  studied  for  their
antileishmanial properties. The structures of the compounds are given in Figure 1.
Figure 1. Structure of the characterized antileishmanial constituents of licorice [1].
1.1. Leishmaniasis
Before going into the mechanistic details of these compounds, a brief idea about leishmaniasis
will help understand the infection biology and the target of action of these molecules.
Leishmania is a protozoan parasite that causes a spectrum of diseases ranging from the self-
healing cutaneous to fatal visceral leishmaniasis. The visceral leishmaniasis particularly affects
the spleen, liver and bone marrow [2]. It is highly endemic in the Indian subcontinent and East
Africa. It is second only to malaria in annual worldwide fatalities due to protozoal infections
[3–4].
1.2. Life cycle
Leishmania parasites remain in nature by transmission between the mammalian hosts
through infected female sandfly bite. Leishmania lifecycle is characterized by having three
developmental stages: procyclic promastigotes, metacyclic promastigotes and the amasti-
gotes (Figure 2).
Figure 2. Lifecycle stages of Leishmania sp [2].
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1.3. Transmission
In the sandfly (Phlebotomus and Lutzomyia spp) gut, the promastigote form of the parasite is
seen which subsequently transforms to the infective metacyclic form which are regurgitated
and injected in the skin of the mammalian host. Infected promastigotes then transforms to the
amastigote form in the mammalian host. In a subsequent blood meal of this infected host, the
amastigote forms are taken up which then transforms to the promastigotes in the gut and the
cycle continues (Figure 3).
Figure 3. Schematic 3D view of the phases of interaction between the Leishmania parasite and sandfly and between the
parasite and the vertebrate cells. “(A) Attachment of a promastigote to the macrophage surface. (B) The process of in-
ternalization via phagocytosis begins with the formation of pseudopods. (C) Leading to the formation of the parasito-
phorous vacuole (PV). In the PV, the promastigote transforms into an amastigote. (D) Recruitment and fusion of host
cell lysosomes with the PV takes place. (E) In the PV, amastigotes divide several times. (F–G) Intense multiplication
generates several hundreds of amastigotes. (H) The host cell bursts, and the parasites reach the extracellular space. (I)
Schematic view of female sandfly showing the digestive tract. (J) During a blood meal, a female sandfly ingests infect-
ed macrophages with amastigote forms present in the blood of the vertebrate host. (K) Amastigotes form ‘nest cells’ in
the abdominal midgut. (L) Amastigotes transform into procyclic promastigotes. (M) Promastigotes multiply and attach
to the midgutepithelium. (N) Parasites migrate toward the anterior midgut, resume replication and start to produce
promastigote secretory gel (PSG). (O) Promastigotes transform into infective metacyclic promastigotes. (P) Metacyclic
promastigotes infect a new mammalian host via regurgitation during the blood meal. These images are based on mi-
crographs obtained by scanning and transmission electron microscopy and by video microscopy” [5].
1.4. Disease manisfestation
Visceral leishmaniasis patients show signs of systemic infection which include fever, fatigue,
weakness, loss of appetite and weight loss. The parasite invades the blood and reticulo-
endothelial system, such as enlarged lymph nodes, spleen and liver. Darkening of the skin,
popularly known as kala azar, which means black fever in Hindi, is infrequent. Anemia which
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is worsened by hypersplenism, leucopenia or thrombocytopenia, and hypergammaglobuli-
nemia are characteristic. Untreated disease in any age group in time can produce profound
cachexia, multisystem disease, bleeding, susceptibility to secondary infections and death [6].
1.5. Current treatment options
For visceral leishmaniasis, treatment is always recommended due to the fatal nature of the
disease. The only treatment currently available for leishmaniasis relies on chemotherapy [7]
as no vaccine has been successfully developed till date for humans. The first line of classical
drug for treatment of leishmaniasis includes pentavalent antimonials, stibogluconate or me-
glumine antimonite. Pentavalent antimonials have been the drug of choice for more than 50
years [8–10]. Other common drugs are pentamidine, allopurinol, amphotericin B, imida-
zoles, miltefosine and paromomycin among others. Even though these drugs are effective
other problems associated with these are (1) there lengthy regimens (weeks to months), (2)
invasive modes of administration (intramuscular or intravenous) and (3) high drug-related
toxicity along with the high cost of therapy which is beyond the capacity of many as this
disease is known to be the ‘disease of the poor’[10, 11]. All these factors together may lead
to the patients discontinuing there therapies in the mid which have resulted in emergence
of drug-resistant parasite strains adding to the list of problems associated with antileishma-
nial therapies [9, 11, 12].
To add to these overwhelming situations, emergence of coinfection collaterally with increasing
incidences of HIV has decreased the number of options available to patients. As we will see in
this chapter that immunosuppression is a key for parasite survival drugs, which can modulate
host immune defenses, should be considered for effective treatment of leishmaniasis. Devel-
opment of vaccines has remained a challenge; however, a canine vaccine has been developed,
and it is in use in South America [13]. At present, no immunization options are available against
leishmaniasis in humans.
1.6. Subversion of host defense
Like any other successful pathogens, Leishmania has also developed strategies to evade host
immune mechanisms in order to survive within the host. A significant number of virulence
factors discovered in Leishmania are directed against circumventing the host immune response.
Apart from these, the parasite also has the ability to maintain a chronic infectious state within
its host by modulation of regulatory factors, which exemplifies the extent on its immune
evasion potential. Indeed, the ongoing battle between the robust immune response mounted
by a host and the counter evasion strategies by the parasite ultimately decides the fate of the
disease.
All these further establishes the fact that a chemotherapeutic alone is not enough to treat this
intelligent parasite, and indeed an immunomodulator which can activate hosts own defense
mechanism will be a better adjunct to the current line of treatment, which is relatively better
in terms of toxicity, efficacy and mode of administration.
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2. 18β-Glycyrrhetinic acid (GRA)
18β-Glycyrrhetinic acid (GRA), a pentacyclic triterpene derivative of the β-amyrin type, is
obtained from the roots of Glycyrrhizza glabra L. It is known to exhibit a variety of pharmaco-
logical effects like antiulcerative, anti-hepatotoxic, anti-tumorigenic and immunoregulatory
activities [14–17]. As evident, GRA has potent immunomodulatory effects, thus its potency as
an antileishmanial agent and the underlying mechanism was thoroughly explored.
2.1. Cytotoxicity
The first and foremost criteria for evaluation of a drug for its antiparasitic activity would be to
evaluate its cytotoxic effects. The development of new drugs that has immunomodulatory
properties requires both pharmacokinetic and toxicity studies to be carried out in conjunction
to clinical verification. Our work so far has shown that GRA is relatively a nontoxic compound
with up to 1.5 g/day consumption in humans [18].
GRA exhibited potent in vitro activity against intracellular L. donovani amastigotes (IC50, 4.3
μg/ml); it was devoid of any obvious cytotoxicity on macrophage host cells, because the
cytotoxic concentration causing 50% cell death was ~100 μg/ml [19]. The infected mice treated
with GRA were completely cured. Moreover, this therapy was seen to be effective in mice with
established disease-progressive Th2 response. After treatment and resolution of parasitism,
the cytokine profile indicated a switch to a protective Th1 pattern associated with upregulation
of NO [19].
2.2. Mechanism
2.2.1. Macrophage activation by NF-κB-mediated nitric oxide and proinflammatory cytokine production
Once the cytotoxic parameters were found satisfying the mechanistic profile was explored. The
disease resolving property of GRA could be attributed to the production of NO and proin-
flammatory cytokines such as IL-12 [20, 21]. The most diversely studied mechanism that assists
the Leishmania survival is modulating the macrophage cytokines production to bias the
immune response to its benefit [22, 23]. Leishmania mainly inhibits the secretion of macrophage
proinflammatory or disease resolving cytokines, which include interleukin 12 (IL-12), tumor
necrosis factor alpha (TNF-α), interferon gamma (IFN-γ) and aids the secretion of anti-
inflammatory or disease promoting cytokines interleukin 10 (IL-10), transforming growth
factor beta (TGF-β) for its own benefit.
Cytokine IL-12 is downregulated by Leishmania via ligation with macrophage receptors
[22, 23]. One of the most important initial signaling events is the release of IL-12 by the
infected macrophage, leading to subsequent priming of the Th1 response and production
of IFN-γ [5, 24–26]. Leishmania also upregulates the production of anti-inflammatory cyto-
kines such as IL-10. IL-10 is important in suppressing macrophage leishmanicidal activity
by opposing IFN-γ [22, 24, 27], nitric oxide (NO) and IL-12 production [28].
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The killing of intracellular Leishmania parasites by GRA correlated with the induction of the
iNOS pathway. Nitric oxide (NO) is known to mediate many of the cytotoxic and immuno-
logical effects upon pathogenic challenge. This NO production has been shown to be depend-
ent upon the inducible for of the nitric oxide synthases (iNOS) [29], whereas under normal
physiological conditions only the constituitive forms of NOS (cNOS) are functional. Induction
of iNOS in turn is under transcriptional regulation of NF-κB, a group of transcription factors
that belong to the Rel protein family. The activated form of NF-κB is a heterodimer, which
usually consists of two proteins, p65 (RelA) and p50 subunit [30]. In unstimulated cells, NF-
κB is found in the cytoplasm bound to an inhibitor, inhibitor of nuclear factor κB (IκB)α and
IκBβ [31]. This association prevents nuclear translocation of NF-κB and hence iNOS transcrip-
tion and NO production. Upon pathogenic challenge, the large multisubunit protein kinase,
inhibitor of nuclear factor kappa-B kinase subunit beta(IKK) causes rapid proteasomal
degradation of IκBα, thereby releasing NFκB and allowing its nuclear translocation. This event
is inhibited in Leishmania donovani infection thereby promoting parasite survival [19] (Figure 4).
Figure 4. GRA promotes NF-κB-mediated parasite killing.
GRA, on the other hand, activates NF-κB through the regulation of genes essentially involved
in encoding proinflammatory cytokines and inflammatory mediators such as NO. L. donovani
infection suppressed NF-κB activation and translocation which was restored upon GRA
administration via induction of IκBα phosphorylation. This in turn was achieved by modu-
lating the upstream signal leading to IKK (inhibitor of nuclear factor kappa-B kinase subunit
beta) activation, that is, without directly interfering with IKK (inhibitor of nuclear factor kappa-
B kinase subunit beta). Overall this signaling activation by GRA led to degradation of IκBα
leading to the translocation of NF-κB in the nucleus and transcriptional activation of iNOS and
proinflammatory cytokines [19] (Figure 4). The antileishmanial activity of GRA was dependent
on the iNOS activity and NO production was further justified by addition of a specific NOS
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inhibitor, NG-monomethyl-L-arginine (NMMA). Upon administration of NMMA along with
GRA, a reduction in the parasite killing capability of GRA was seen and withdrawal of NMMA
led to decreased parasite survival indicating a role of GRA-induced NO-mediated parasite
killing.
2.2.2. MAPK and phosphatases
Mitogen-activated protein kinase(MAPK) plays an important role in activation of NF-κB.
MAPK signaling cascades are rather complex events which ultimately results in manifold
increase in stimulus-mediated responses. However, if this response remains unchecked, it
may be detrimental for the cells and thus a balance between the activity of the kinases and
phosphatases play important roles in physiological scenario. In macrophages, the MAPK
(mitogen-activated protein kinase) cascade and the NF-κB pathway play important roles in
the regulation of functions involved in inflammation and host defense. L. donovani success-
fully sabotage these pathways creating an anti-inflammatory milieu by inhibiting produc-
tion of NO and proinflammatory cytokines thereby strengthening their existence within the
macrophages [32]. Thus, the agents that can activate NF-κB pathway creating a proin-
flammtory milieu potent enough to kill the parasites might prove attractive candidates to
control Leishmania infection. Our studies also revealed that the Mitogen-activated protein
kinase kinase - extracellular signal regulated kinases(MEK-ERK ) pathway.
Figure 5. The balance between kinases and phosphatases is restored upon GRA treatment.
pathway is compensated in infected cells [33]. GRA, the triterpenoid is an ideal candidate both
because of its pharmacologically safe parameters and immunomodulatory properties [19]. The
switching of the immunological response was found to be dependent upon the MAPK
(mitogen-activated protein kinase) activation among which only ERK and p38 were found to
be regulated by GRA [34]. In Leishmania infection, these MAPK (mitogen-activated protein
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kinase) activation was severely compensated which was in turn is attributed to the fact that
activity of MAPK (mitogen-activated protein kinase) phosphatases, which dephosphorylate
and thereby inactivate MAPK (mitogen-activated protein kinase), significantly increased. This
corroborated with the fact that inhibition of SHP-1, a MAPK (mitogen-activated protein kinase)
phosphatase led to stronger proinflammatory responses against infection [35]. However, GRA
treatment could potentially inhibit the activity of the phosphatases, thereby shifting the total
kinase to phosphatase balance in favor of creating an antileishmanial milieu [34] (Figure 5).
Figure 6. GRA activates p38 via the TLR2/4 pathway.
2.2.3. Downregulation of toll-like receptor (TLR) pathways
Toll-like receptor (TLR) expressed on the cells of the innate immune system are critical for
recognition of pathogen-associated molecular patterns (PAMP). Upon ligand binding, the TLR
gets activated leading to downstream signaling cascade activation leading to NF-κB- and
MAPK (mitogen-activated protein kinase)-mediated proinflammatory cytokine production.
The TLR2 agonists used to activate TLR2 signaling pathway showed host protective immune
response resulting in parasite clearance from L. donovani infected macrophages [36]. To subvert
this inflammatory response Leishmania either recruits suppressors of the cytokine signaling
(SOCS) family proteins, SOCS-1/3 [37], or activates host de-ubiquitinating enzyme A20 to
negatively regulate TLR2/4-induced host protective response [38, 39]. Leishmania can alter
TLR4 signaling to favor its establishment within the macrophages. TLR4-mediated macro-
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phage activation was shown to be suppressed in Leishmania infection through the release of
TGF-β [40]. L. mexicana capitalizes on TLR4 signaling to inhibit the production of IL-12 by
infected macrophages and promotes parasite establishment [41]. Other TLRs involved in
infection with Leishmania include TLR3 and TLR9.
The effect of GRA is mediated by means of MAPK (mitogen-activated protein kinase) activa-
tion and phosphatase downregulation. Deeper analysis revealed that the MAPK (mitogen-
activated protein kinase) p38 activation was dependent on GRA-mediated canonical and
noncanonical activation where numerous upstream molecules play important roles [42]. This
study further highlighted the importance of p38 MAPK (mitogen-activated protein kinase) in
GRA-mediated parasite elimination and its activation by upstream kinases like MKK3/6 which
itself is dependent upon upstream signaling molecules (Figure 6).
Figure 7. Mode of Action of 18β-Glycyrrhetinic Acid-potent antileishmanial immunomodulator. Leishmania (i) inhibits
p38 phosphorylation, (ii) activates phosphatases, (iii) inhibit activation of NFκB thereby leading to (iv) inhibition of
proinflammatory cytokine reponses. 18β-Glycyrrhetinic Acid acts as an immunomodulator which in infection activates
(a) canonical and (b) non canonical pathways leading to phosphorylation and activation of p38, (c) activates IκB Kinase
which in turn results in IκBα phosphorylation and degradation leading to NFκB phosphorylation and activation, (d)
inhibit phosphatases which would otherwise lead to dephosphorylation and inhibition of major kinases therby pro-
moting proinflammatory cytokine response generation and (e) parasite killing.
Thus, the effective macrophage activation via NO and proinflammatory cytokines production
in response to GRA treatment justifies the candidature of this potent immunomodulator as an
antileishmanial. Furthermore, this compound may prove to be effective in terms of generating
immunity not only in nonhealing leishmaniasis but also for the treatment of other chronic
infectious diseases. A comprehensive model giving the overall mechanistic insight into the
mode of action of GRA as antileishmanial agent will help in deducing its function in other
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intramacrophage pathogens which assume similar immunoevasive mechanisms to escape host
defenses (Figure 7).
3. Glycyrrhizic acid
Another constituent of licorice, which serves as an antileishmanial compound, is glycyrrhizic
acid (GA) [43]. The studies using this compound showed an increase in NO production with
restoration of Th1 cytokine balance and inhibition of immunosuppressive prostaglandin
E2(PGE2) production. This is in line with recent evidences, which suggests that the parasite is
able to induce PGE2 production via promoting inducible COX2 expression. This in turn
resulted in activation of EP receptors (PGE2 receptors) on the host cell surface thereby causing
Cyclic adenosine monophosphate(cAMP) induction and cytokine production [44] (Figure 8).
Figure 8. Glycyrrhizic acid mediated PGE2 inhibition and NO and proinflammatory cytokine production helps para-
site suppression.
This is also anticipated as glycyrrhizic acid is readily hydrolyzed to glycyrrhetinic acid in
human body [45] which is already discussed in details to have antileishmanial activities. Recent
studies further shows that this compound when used in conjunction with antimonials can help
in overcoming the resistance seen in the antimony resistant parasites. Extensive use of the
antimonials and low follow-up of cases had led to emergence of antimonial resistant strains
of the parasite [46]. The main criteria for this resistance is attributed to the overexpression and
efflux activity of a class of transporters on the surface of the host cells namely P-glycoprotein
(P-gp) and multidrug resistance-associated protein (MRP-1) thereby leading to efflux of the
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antimonials and parasite persistence. However, administration of glycyrrhizin led to suppres-
sion of these transporters and simultaneously shifted the overall anti-inflammatory milieu to
the proinflammatory one [46] (Figure 9). Thus, this herbal compound can serve as an econom-
ical effective counterpart to its expensive counterparts like miltefosine and amphotericin B.
Further studies demonstrated the role of glycyrrhizin in mediating proliferation of T cells,
thereby promoting disease resolving IFN-γ production in Leishmania infected cells. This was
in turn an effect of suppression of COX-2 by glycyrrhizin on the myeloid-derived suppressor
cells, a heterogeneous population of precursor cells, which promotes parasite survival by
suppressing T cell functions [47].
Figure 9. Glycyyrhizic acid (GA) suppresses P-gp and MRP-1 activation leading to antimonial retention and parasite
inhibition.
4. Licochalcone A
The oxygenated chalcone, licochalcone A, has also been extensively studied to understand the
mechanism of this compound as an antileishmanial agent [48–50]. Previous studies have
shown its effect as antioxidant, antimicrobial and anti-tumor promoting properties [51, 52].
The use of this compound in infection particularly affected the amastigote forms of the parasite
and to a lesser extent the promastigote form having practically no effect on the host monocytes
even at higher concentrations. The main target of licochalcone A was the mitochondrion of the
parasite, whereas the host mitochondrion remained unaffected [48]. The reason for the same
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is still unknown but further studies suggested that the parasite respiratory rate was affected
resulting in an overall decrease in parasite O2 consumption and CO2 production with a decrease
in the activity of the mitochondrial dehydrogenases [50]. In vivo studies also showed high
parasite elimination in in vivo studies upon intraperitoneal administration of licochalcone A
as opposed to intralesional or oral administration [49]. All these findings suggests potential
role of licochalcone A as an antileishmanial agent although studies understanding the
mechanism of this compound is still underway (Figure 10).
Figure 10. The effect of licochalcone A on the mitochondrion of the Leishmania parasite.
5. Conclusion
All these compounds have effectively showed their potential as antileishmanial agents. Future
works leading to clinical trials of these compounds alone or in conjunction with present
chemotherapeutics may highly benefit the Leishmania distressed people. Overall the immuno-
modulators of the herbal origin like licorice and its constituents open up avenues for formu-
lation of cost-effective and low-toxicity drugs for diseases with limited treatment.
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